|本期目录/Table of Contents|

[1]阮园,查敏,叶丽芳,等.胰岛素强化序贯利拉鲁肽治疗2型糖尿病合并肥胖患者的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2021,23(02):122-125.[doi:10.3969/j.issn.1672-271X.2021.02.003]
　RUAN Yuan,ZHA Min,YE Li-fang,et al.Effect of liraglutide treatment after intensive insulin therapy on type 2 diabetes with obesity[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(02):122-125.[doi:10.3969/j.issn.1672-271X.2021.02.003]
点击复制

胰岛素强化序贯利拉鲁肽治疗2型糖尿病合并肥胖患者的疗效观察()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年02期
页码:
122-125
栏目:
临床研究
出版日期:
2021-03-22

文章信息/Info

Title:
Effect of liraglutide treatment after intensive insulin therapy on type 2 diabetes with obesity
作者:
阮园; 查敏; 叶丽芳; 张舒; 贾佳; 王丽娟; 徐巍龙; 周静波; 余旭; 余江毅
210029南京，南京中医药大学附属医院(江苏省中医院）内分泌科（阮园、查敏、叶丽芳、张舒、贾佳、王丽娟、徐巍龙、周静波、余旭、余江毅）
Author(s):
RUAN Yuan;  ZHA Min; YE Li-fang;  ZHANG Shu;  JIA Jia;  WANG Li-juan;  XU Wei-long;  ZHOU Jing-bo;  YU Xu; YU Jiang-yi
(Department of Endocrinology，Affiliated Hospital of Nanjing University of Chinese Medicine/Jiangsu Province Hospital of TCM，Nanjing 210029，Jiangsu, China)
关键词:
利拉鲁肽; 胰岛素; 肥胖症; 2型糖尿病; 脂代谢障碍
Keywords:
liraglutide;  insulin;  obesity;  type 2 diabetes;  lipid metabolism disorders
分类号:
R587.1
DOI:
10.3969/j.issn.1672-271X.2021.02.003
文献标志码:
A
摘要:
目的探讨胰岛素强化序贯利拉鲁肽治疗２型糖尿病伴有肥胖症状患者的临床疗效。方法回顾性分析2017年1月至2019年12月江苏省中医院内分泌科收治的80例2型糖尿病合并肥胖患者的临床资料，按治疗方法不同分为2组，每组40例，对照组给予胰岛素强化治疗联合二甲双胍序贯甘精胰岛素治疗, 利拉鲁肽组给予胰岛素强化治疗联合二甲双胍序贯利拉鲁肽治疗，疗程12周。对比分析2组患者治疗前后的体重指数（BMI）、血糖相关指标（FPG、2hPG、HbAlc）、血脂相关指标（TC、TG、HDL-C、LDL-C）、炎症相关指标（IL-6、TNF-α）水平的变化情况。结果治疗前，2组BMI、血糖相关指标、血脂相关指标、炎症相关指标相比较，差异均无统计学意义(P>0.05)。治疗后，利拉鲁肽组BMI[(26.40±1.60)kg/m2]、FPG[(6.95±0.82)mmol/L]、2hPG[(7.49±0.95)mmol/L]、HbA1c[(7.02±0.82)%]水平低于对照组[(28.7±1.9)kg/m2、(7.02±1.01）mmol/L、(8.92±1.01）mmol/L、(7.56±0.84)%]；TC[(4.60±1.09)mmol/L]、TG[(0.90±0.79)mmol/L]、HDL-C[(1.60±0.24)mmol/L]、LDL-C[(2.60±0.78)mmol/L]水平低于对照组[(6.10±0.96)mmol/L、(1.50±0.57)mmol/L、(1.30±0.32)mmol/L、(3.00±0.45)mmol/L]；IL-6[(9.64±1.05)ng/L]、TNF-α[(28.85±5.32)ng/L]水平低于对照组[(12.34±1.83)ng/L、(36.08±5.17)ng/L]，差异均有统计学意义(P<0.01)。结论胰岛素强化序贯利拉鲁肽治疗２型糖尿病合并肥胖患者能够有效地控制血糖、体重，改善血脂代谢,减轻炎性反应，具有较高的临床应用价值。
Abstract:
ObjectiveTo investigate the clinical effect of insulin - enhanced sequentiallalutide in the treatment of type 2 diabetes mellitus with obesity.MethodsThe clinical data of 80 patients with type 2 diabetes and obesity were retrospectively analyzed. They were divided into two groups according to different treatment methods, each with 40 cases. The control group had glargine therapy after intensive insulin therapy combined with metformin, and the observation had liraglutide therapy after intensive insulin therapy combined with metformin for 12 weeks. The indexes of BMI, FPG, 2hPG, HbAlc, TC, TG, HDL-C, LDL-C, IL-6, TNF-α were analyzed.ResultsBefore treatment, there were no statistically significant differences of BMI, FPG, 2hPG, HbAlc, TC, TG, HDL-C,LDL-C, IL-6, TNF-α between the two groups (P>0.05). After treatment, BMI [(26.40±1.60)kg/m2], FPG [(6.95±0.82)mmol/L], 2hPG [(7.49±0.95)mmol/L], HbA1c [(7.02±0.82)%] were lower in the observation group than that in the control group [(28.70±1.90)kg/m2, (7.02±1.01)mmol/L, (8.92±1.01)mmol/L, (7.56±0.84)%]. TC[(4.60±1.09) mmol/L], TG [(0.90±0.79)mmol/L], HDL-C [(1.60±0.24)mmol/L], LDL-C [(2.60±0.78)mmol/L] were lower in the observation group than that in the control group [(6.10±0.96)mmol/L, (1.50±0.57)mmol/L, (1.30±0.32)mmol/L, (3.00±0.45)mmol/L]. IL-6 [(9.64±1.05)ng/L ], TNF-α [(28.85±5.32)ng/L] were lower in the observation group than that in the control group [(12.34±1.83)ng/L, (36.08±5.17)ng/L](P<0.01).ConclusionLiraglutide treatment after intensive glycemic control with insulin therapy for patients with type 2 diabetes and obesity is effective in controlling blood sugar, lowering body weight, regulating blood lipid metabolism, reducing inflammatory response, which has high value of clinical application.

参考文献/References:

[1]Bae JP, Lage MJ, Mo D, et al. Obesity and glycemic control in patients with diabetes mellitus: analysis of physician electronic health records in the US from 2009-2011[J]. J Diabetes Complications，2016,30（2）:212-220.
[2]陈俊秀，孙中帅，郑周琴，等. 2型糖尿病患者血糖波动与体重指数相关性研究[J].医学研究生学报,2020,33(8):835-838．
[3]Kenkre J, Tan T, Bloom S. Treating the obese diabetic[J]. Expert Rev Clin Pharmacol, 2013,6（2）:171-183.
[4]Home P, Riddle M, Cefalu WT, et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges?[J] Diabetes Care, 2014,37（6）:1499-1508.
[5]Davies MJ, Bergenstal R, Bode B, et al. NN8022-1922 Study Group. Efficacy of liraglutide for weight loss among patients with type 2diabetes: the SCALE diabetes randomized clinical Trial[J]. JAMA, 2015,314（7）:687-699.
[6]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013版)[J].中华糖尿病杂志,2014,6(7):447-498．
[7]周翔海. 肥胖合并Ⅱ型糖尿病患者的特征分析-基于患者的临床研究[J].中国糖尿病杂志，2013,21(6):575-576．
[8]Halawi H, Khemani D, Eckert D, et al. Effectsof liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo controlled pilot trial[J]. Lancet Gastroenterol Hepatol,2017,2（12）:890-899.
[9]王春华，苏建彬，王雪琴.不同HbA1c水平2型糖尿病患者的胰岛细胞功能比较[J]. 东南国防医药，2020,22(2):156-160．
[10]Bajaj HS, Venn K, Ye C, et al. Lowest glucose variability and hypoglycemia are observed with the combination of a GLP-1 receptor agonist and basal insulin (VARIATION study)[J]. Diabetes Care,2017,40（2）:194-200.
[11]Rawshani A, Rawshani A, Franzen S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes[J].N Engl J Med, 2018, 379(7):633-644.
[12]Ostergaard L, Frandsen CS, Madsbad S. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Rev Clin Pharmacol[J]. 2016,9(2): 241-265.
[13]Kochar IS, Sethi A. Efficacy and safety of liraglutide in Indian adolescents with obesity[J]. Obes Sci Pract, 2019, 5（3）: 251-257.
[14]Kaneko S, Nishijima K, Bosch-Traberg H, et al. Efficacy and Safety of Adding Liraglutide to Existing Insulin Regimens in Japanese Patients With Type 2 Diabetes Mellitus: A Post-Hoc Analysis of a Phase 3 Randomized Clinical Trial[J]. J Diabetes Investig，2018,9(4):840-849.
[15]Overbeek JA, Heintjes EM, Huisman EL, et al.Clinical Effectiveness of Liraglutide vs Basal Insulin in a Real-World Setting: Evidence of Improved Glycaemic and Weight Control in Obese People With Type 2 Diabetes[J]. Diabetes Obes Metab, 2018, 20(9):2093-2102.
[16]Ahmann A, Rodbard HW, Rosenstock J,et al. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial[J]. Diabetes Obes Metab, 2015, 17(11): 1056-1064.

相似文献/References:

[1]赖晓荣,朱欣娟,黄银霞.胰岛素泵在骨折合并糖尿病患者围手术期的应用及护理[J].医学研究与战创伤救治(原医学研究生学报),2012,14(01):76.
[2]吴 刚,董春霞,黄少南,等.运动疗法对抗精神病药物所致精神分裂症患者糖代谢异常的干预研究[J].医学研究与战创伤救治(原医学研究生学报),2012,14(04):339.
　WU Gang,DONG Chun-xia,HUANG Shao-nan,et al.Clinical study on exercise therapy of abnormal glucose metabolism caused by antipsychotic drugs in patients with schizophrenia[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(02):339.
[3]过贵元,胡淑鸾,刘小朋.胰岛素对兔视网膜Müller细胞生长活性的影响[J].医学研究与战创伤救治(原医学研究生学报),2011,13(01):14.
　GUO Gui-yuan,HU Shu-luan,LIU Xiao-peng.Effects of insulin on the proliferation of rabbit retinal Müller cells[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2011,13(02):14.
[4]张 昊,张景红,倪志明,等.胰岛素腹腔内用药治疗2型糖尿病腹膜透析11例[J].医学研究与战创伤救治(原医学研究生学报),2011,13(01):68.
[5]李玉梅,翟成娟,曹 涌.微量泵输注与皮下注入胰岛素对体外循环术后患者血糖的比较[J].医学研究与战创伤救治(原医学研究生学报),2011,13(05):458.
[6]谭擎缨,姚佳琦,王秀景,等.腹腔内脏脂肪面积与2型糖尿病及血清胰岛素的相关研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):12.[doi:10.3969/j.issn.1672-271X.2015.01.004]
　TAN Qing-ying,YAO Jia-qi,WANG Xiu-jing,et al.A association of visceral adipose area with type 2 diabetes and serum insulin[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(02):12.[doi:10.3969/j.issn.1672-271X.2015.01.004]
[7]税迎春,夏欣一,章 琼,等.四氧嘧啶糖尿病妊娠大鼠二肽基肽酶4活性变化[J].医学研究与战创伤救治(原医学研究生学报),2015,17(06):568.[doi:10.3969/j.issn.1672-271X.2015.06.003]
　SHUI Ying-chun,XIA Xin-yi,ZHANG Qiong,et al.Changes of DPP4 enzyme activity in alloxan-induced diabetic pregnant rat[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(02):568.[doi:10.3969/j.issn.1672-271X.2015.06.003]
[8]赵恒霞,杨小燕,侯彩云,等.平行定位标识法管理对糖尿病患者胰岛素注射效果研究[J].医学研究与战创伤救治(原医学研究生学报),2021,23(02):201.[doi:10.3969/j.issn.1672-271X.2021.02.021]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（81704022）；江苏省第十四批“六大人才高峰”高层次人才选拔培养项目（WSN-088）
更新日期/Last Update: 2021-03-22